A detailed history of Walleye Capital LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 248,288 shares of CPRX stock, worth $5.28 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
248,288
Holding current value
$5.28 Million
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.19 - $21.35 $3.77 Million - $5.3 Million
248,288 New
248,288 $4.94 Million
Q1 2024

May 15, 2024

BUY
$13.18 - $17.11 $280,760 - $364,477
21,302 New
21,302 $339,000
Q3 2023

Nov 14, 2023

BUY
$11.69 - $15.02 $101,118 - $129,923
8,650 Added 72.7%
20,549 $240,000
Q2 2023

Aug 14, 2023

BUY
$11.5 - $18.08 $136,838 - $215,133
11,899 New
11,899 $159,000
Q2 2020

Aug 14, 2020

SELL
$3.48 - $5.05 $41,760 - $60,600
-12,000 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$2.61 - $5.21 $31,320 - $62,520
12,000 New
12,000 $46,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.19B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.